Search Results

You are looking at 1 - 10 of 23 items for :

  • aggressive pituitary adenomas x
Clear All
Open access

Adrian F Daly, David A Cano, Eva Venegas-Moreno, Patrick Petrossians, Elena Dios, Emilie Castermans, Alvaro Flores-Martínez, Vincent Bours, Albert Beckers and Alfonso Soto-Moreno

neurosurgery, medical therapy and radiotherapy can be needed to treat pituitary adenomas ( 4 , 5 , 6 , 7 ). There is an increased likelihood of aggressive pituitary adenoma characteristics (early age at diagnosis, large tumor size, increased invasiveness

Open access

Anastasia P Athanasoulia-Kaspar, Kathrin H Popp and Gunter Karl Stalla

non-functioning pituitary adenomas (NFPA) without history of dopaminergic treatment. The total prevalence of ICDs was significantly higher in patients with prolactinomas (24.6%-referring to the prevalence of one or more ICD) compared to the NFPA group

Open access

Adrian F Daly, Liliya Rostomyan, Daniela Betea, Jean-François Bonneville, Chiara Villa, Natalia S Pellegata, Beatrice Waser, Jean-Claude Reubi, Catherine Waeber Stephan, Emanuel Christ and Albert Beckers

pituitary adenoma (FIPA) kindreds and young patients, reaching nearly 30% in those with pituitary gigantism ( 8 ). AIP mutations confer a series of important aggressive characteristics in acromegaly. As compared with non-mutated acromegaly patients, those

Open access

G Giuffrida, F Ferraù, R Laudicella, O R Cotta, E Messina, F Granata, F F Angileri, A Vento, A Alibrandi, S Baldari and S Cannavò

reported during the following 3 years. Review of literature Until now, extensive data about effectiveness and safety of PRRT are reported in literature for other nine patients with pituitary carcinomas or aggressive adenomas ( 13 , 14 , 15 , 16

Open access

Morten Winkler Møller, Marianne Skovsager Andersen, Christian Bonde Pedersen, Bjarne Winther Kristensen and Frantz Rom Poulsen

Ieva A Rotondo F Syro LV Cusimano MD Kovacs K. Aggressive pituitary adenomas – diagnosis and emerging treatments . Nature Reviews Endocrinology 2014 10 423 – 435 . ( https://doi.org/10.1038/nrendo.2014.64 ) 24821329 10.1038/nrendo

Open access

Aida Javanbakht, Massimo D’Apuzzo, Behnam Badie and Behrouz Salehian

adenomas, metastatic tumors, when detected, are more likely to be located in the posterior pituitary. This likely accounts for diabetes insipidus (DI) being more common in patients with Pit Met than patients with other pituitary pathology. The exact

Open access

Kunal Thakkar, Swati Ramteke-Jadhav, Rajeev Kasaliwal, Saba Samad Memon, Virendra Patil, Puja Thadani, Nilesh Lomte, Shilpa Sankhe, Atul Goel, Sridhar Epari, Naina Goel, Anurag Lila, Nalini S Shah and Tushar Bandgar

non-neoplastic etiologies can be found in this region ( 1 ). Pituitary adenomas are the commonest SSR tumors accounting for 85% of sellar masses ( 2 ). Amidst the non-adenoma masses, other common sellar lesions include craniopharyngioma (CR, 12

Open access

Solène Castellnou, Alexandre Vasiljevic, Véronique Lapras, Véronique Raverot, Eudeline Alix, Françoise Borson-Chazot, Emmanuel Jouanneau, Gérald Raverot and Hélène Lasolle

://doi.org/10.1111/cen.13146 ) 5 Raverot G Wierinckx A Jouanneau E Auger C Borson-Chazot F Lachuer J Pugeat M Trouillas J . Clinical, hormonal and molecular characterization of pituitary ACTH adenomas without (silent corticotroph adenomas) and

Open access

Sara Storvall, Helena Leijon, Eeva Ryhänen, Johanna Louhimo, Caj Haglund, Camilla Schalin-Jäntti and Johanna Arola

indicating aggressive tumor behavior in PC and APA exist, such as a high Ki-67 percentage (>5%) ( 2 , 12 ). A negative parafibromin stain is present in up to 75% of sporadic PCs, but rarely in adenomas ( 13 , 14 ). Parafibromin is encoded by CDC73 , a

Open access

Boju Pan, Anqi Wang, Junyi Pang, Yuhan Zhang, Ming Cui, Jian Sun and Zhiyong Liang

parathyroid adenoma and carcinoma. Numerous studies have revealed PD-L1 expression in endocrine tumors, including pituitary tumors ( 11 ), papillary thyroid carcinomas ( 12 , 13 ), adrenocortical carcinomas ( 14 ), pheochromocytomas ( 15 ) and